Viracta Therapeutics, Inc. — Cyborg Score 3/10

Strategic Profile

The company contributes to a growing body of research aimed at tackling malignancies that are difficult to treat with conventional therapies. Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for relapsed/refractory EBV+ lymphoma, and a Phase 1b/2 trial for EBV+ recurrent or metastatic nasopharyngeal carcinoma.

Cyborg Score Rationale

Current market capitalization is approximately $388.7K with zero trailing twelve months revenue and negative net income of $10.5M. The company faces severe liquidity and financial constraints typical of early-stage biotech, though the novel mechanism and unmet medical need provide scientific merit.

Top Insights

• Clinical-stage company with no approved products or revenue; dependent on trial success for viability
• Novel viral gene activation mechanism targeting EBV-positive cancers represents differentiated approach in precision oncology
• Trading on OTC Markets with severe delisting risk and minimal market liquidity
• Pipeline includes vecabrutinib (clinical-stage) and VRx-510 (preclinical) alongside lead Nana-val program

Named Competitors

• Lymphoma treatments — Conventional and targeted lymphoma therapies
• Checkpoint inhibitors — PD-1/PD-L1 inhibitors for solid tumors and hematologic malignancies
• Precision oncology platforms — Cell therapy for virus-associated and other cancers

Recent Developments

• (June 2026) Stock trading at $0.01 with minimal market capitalization and liquidity challenges
• (2025-2026) Ongoing Phase 2 NAVAL-1 trial for EBV+ lymphomas and Phase 1b/2 for nasopharyngeal carcinoma

Open the full interactive Viracta Therapeutics, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.